- Home
- HCM vs BLTE Comparison
HCM vs BLTE Comparison
Compare HCM & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- BLTE
- Stock Information
- Founded
- HCM 2000
- BLTE 2018
- Country
- HCM Hong Kong
- BLTE United States
- Employees
- HCM N/A
- BLTE N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- BLTE Biotechnology: Pharmaceutical Preparations
- Sector
- HCM Health Care
- BLTE Health Care
- Exchange
- HCM Nasdaq
- BLTE Nasdaq
- Market Cap
- HCM 2.6B
- BLTE 2.6B
- IPO Year
- HCM N/A
- BLTE 2022
- Fundamental
- Price
- HCM $15.30
- BLTE $111.81
- Analyst Decision
- HCM Sell
- BLTE Strong Buy
- Analyst Count
- HCM 1
- BLTE 5
- Target Price
- HCM $13.75
- BLTE $105.00
- AVG Volume (30 Days)
- HCM 34.7K
- BLTE 101.9K
- Earning Date
- HCM 08-07-2025
- BLTE 11-10-2025
- Dividend Yield
- HCM N/A
- BLTE N/A
- EPS Growth
- HCM N/A
- BLTE N/A
- EPS
- HCM 0.53
- BLTE N/A
- Revenue
- HCM $602,197,000.00
- BLTE N/A
- Revenue This Year
- HCM N/A
- BLTE N/A
- Revenue Next Year
- HCM $15.49
- BLTE N/A
- P/E Ratio
- HCM $5.70
- BLTE N/A
- Revenue Growth
- HCM N/A
- BLTE N/A
- 52 Week Low
- HCM $11.51
- BLTE $49.00
- 52 Week High
- HCM $19.50
- BLTE $124.73
- Technical
- Relative Strength Index (RSI)
- HCM 49.84
- BLTE 66.19
- Support Level
- HCM $14.40
- BLTE $102.00
- Resistance Level
- HCM $15.36
- BLTE $124.73
- Average True Range (ATR)
- HCM 0.33
- BLTE 6.53
- MACD
- HCM 0.07
- BLTE 0.23
- Stochastic Oscillator
- HCM 64.84
- BLTE 59.73
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.